Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Alfredo Falcone(Azienda Ospedaliera Universitaria Pisana), Carlo Barone(Università Cattolica del Sacro Cuore), Marc Ychou(Inserm), J. Kalmus(Bayer (Germany)), Marc Peeters(Ghent University Hospital), Andrea Spallanzani(University of Modena and Reggio Emilia), Christian Kappeler(Bayer (Germany)), Stefano Cascinu(University of Modena and Reggio Emilia), Evaristo Maiello(Casa Sollievo della Sofferenza), Rocio García‐Carbonero(Hospital Universitario 12 De Octubre), Ralf‐Dieter Hofheinz(Goethe University Frankfurt), Baruch Brenner, Axel Grothey(Mayo Clinic in Arizona), Yull Arriaga(The University of Texas Southwestern Medical Center), Ashok Miriyala(Bayer (United States)), Thierry André(Sorbonne Université), Alberto F. Sobrero(Ospedale Policlinico San Martino), Jean‐François Seitz(Aix-Marseille Université), Maria Banzi(Azienda Ospedaliera S.Maria), Udit Verma(The University of Texas Southwestern Medical Center), Erika Martinelli(University of Campania "Luigi Vanvitelli")
Cited by 143
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k